Finvest
CNTA Biotechnology · Clinical-stage biotech · Merger arbitrage · Sleep medicine · Thesis updated June 30, 2026

Lilly deal now drives CNTA

01 Running thesis

Now a deal-close story

Centessa used to be a high-risk bet on a sleep-drug platform. That changed on March 31, 2026, when the company signed a deal to be bought by Eli Lilly for $38.00 per share in cash, plus a contingent value right, or CVR, worth up to another $9.00 per share.

The bull case is simple. Lilly closes the deal in Q3 2026, shareholders receive the $38.00 cash price, and the CVR later adds value if the required milestones are hit. Lilly’s interest also gives outside validation to Centessa’s Orexin Receptor 2, or OX2R, drug program.

The bear case is also simple. The deal still needs customary closing conditions, including shareholder and regulatory approvals. If it breaks, CNTA would likely stop trading like a near-cash deal and start trading again like a clinical-stage biotech, with all the usual trial, funding, and regulatory risks.

The Q1 2026 10-Q did not add a new problem that changes the deal view. It kept the expected Q3 2026 closing timeline in place, so the next watch items are approval votes, antitrust timing, and final closing.

May 2026→The Q1 2026 10-Q kept the Lilly acquisition thesis intact. It reaffirmed the expected Q3 2026 close and did not add a new material deal issue.
Mar 2026▲Centessa agreed to be acquired by Eli Lilly for $38.00 per share in cash plus a CVR worth up to $9.00 per share. The thesis shifted from standalone biotech risk to merger close and CVR probability.
Nov 2025▲Initial ORX750 Phase 2a data looked positive, with tolerability and efficacy signals across key sleep-wake indications. ORX142 also entered Phase 1 and showed positive early data.
Aug 2025→The Q2 2025 filing confirmed Centessa’s all-in OX2R focus, with much higher spending on that program and cash runway into mid-2027. The main risk remained concentration in one platform.
May 2025→The Q1 2025 filing reinforced the orexin pivot as OX2R spending rose sharply year over year. The company still expected funding into mid-2027.
Mar 2025→Centessa discontinued LB101 and expanded the OX2R pipeline with ORX142 and ORX489. This sharpened the upside, but also increased dependence on one mechanism.
Nov 2024→The initial view centered on Centessa’s pivot away from SerpinPC and toward the ORX750-led OX2R program. Cash of $518.4 million at September 30, 2024 was expected to fund operations into mid-2027.
02 Business model

Research lab in a buyout window

Centessa does not have a marketed drug in the context provided. Its value comes from experimental medicines, mainly OX2R agonists for sleep-wake disorders such as narcolepsy and idiopathic hypersomnia.

Before the Lilly agreement, Centessa’s model was to spend cash on research and development, raise money when needed, and possibly license non-core technology like LockBody. After the agreement, the practical business model is to preserve the company and meet deal closing conditions.

The company reported cash, cash equivalents, and investments of $577.1 million at December 31, 2025, and said that was expected to fund planned operations into mid-2028. That cash cushion matters because it lowers the chance that normal operating funding becomes a deal problem before the expected close.

Shareholder value now has two parts. The first is the fixed $38.00 cash consideration if the merger closes. The second is uncertain CVR value, which depends on later milestones and may be worth nothing.

03 Product portfolio

Sleep drugs carry the CVR

Growth engine

ORX750, also called cleminorexton

ORX750 is the lead oral OX2R agonist in a Phase 2a study for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Initial data showed it was generally well-tolerated and had statistically significant improvements on key efficacy endpoints.

Option

ORX142

ORX142 is Centessa’s second OX2R agonist candidate. It entered Phase 1 after FDA clearance of its IND, and early data showed positive safety and efficacy signals in healthy volunteers.

Option

ORX489

ORX489 is the third OX2R candidate and was in IND-enabling studies in the internal record. Its value is earlier and less proven, but it broadens the platform beyond one lead asset.

Option

LockBody platform

LockBody is no longer the center of the company, but it still has licensing value. Centessa signed a deal giving Genmab access to the platform for research against up to three targets.

04 Business segments

One company, one main focus

Cleminorexton R&D61%growing fast
Other Orexin platform R&D39%growing fast

Centessa reports as a single business segment. To show operating concentration, the mix below uses 2025 program R&D detail from the internal record: $78.5 million for cleminorexton and $50.9 million for the rest of the Orexin platform, which together equal $129.4 million of broader Orexin platform spend.

05 Risk factors

What could break

Merger fails to close

High impact · Medium odds

The largest risk is that the Lilly transaction is delayed or does not close. The deal needs customary approvals, including shareholder and regulatory approvals. If it fails, CNTA would likely be valued again on standalone clinical prospects, which could be far below the $38.00 cash deal price.

We watchWatch for CNTA shareholder approval, HSR waiting-period expiration or termination, and any company update that moves the expected Q3 2026 closing date.

CVR pays nothing

Medium impact · Medium odds

The CVR can add up to $9.00 per share, but it is not guaranteed. It depends on specific clinical and regulatory milestones after the deal. A closed deal with no CVR payment would cap the return at the cash price.

We watchWatch Lilly and Centessa disclosures for the exact CVR milestones, trial progress, regulatory filings, and any milestone notices.

Regulators slow the deal

Medium impact · Medium odds

Even a deal that eventually closes can lose appeal if timing stretches. Antitrust review or other closing conditions could push cash receipt later than investors expect. A long delay can widen the merger spread and hurt near-term holders.

We watchWatch antitrust filings, HSR status, and any updated closing language in SEC filings or deal communications.

OX2R data disappoints

Medium impact · Medium odds

Clinical risk still matters because the CVR is tied to the success of the drug program. ORX750 has shown positive initial Phase 2a data, and ORX142 has shown positive early data, but later studies can still fail or show safety problems. Any new concern in cardiac, visual, liver, renal, or efficacy results would weaken the CVR case.

We watchWatch future ORX750, ORX142, and ORX489 study updates, especially safety findings and dose-selection decisions.

Business disruption before closing

Medium impact · Low odds

The pending transaction can distract employees, partners, and trial sites. The 10-Q names the risk that the announcement and waiting period could disrupt operations. That matters most if a delay causes key people or study execution to slip.

We watchWatch for trial delays, management departures, unusual spending changes, or new risk language in SEC filings.
06 Quick answers

In one breath

What is Centessa Pharmaceuticals?

Centessa is a clinical-stage biotechnology company focused mainly on OX2R agonists for sleep-wake disorders. Its lead drug candidate is ORX750, also called cleminorexton.

What is Lilly paying for Centessa?

Eli Lilly agreed to buy Centessa for $38.00 per share in cash. Shareholders may also receive a non-transferable CVR worth up to $9.00 per share if certain milestones are met.

What is the main risk for CNTA now?

The main risk is that the Lilly deal does not close on time or at all. If that happens, the stock would likely trade on Centessa’s standalone drug pipeline rather than the cash deal price.

Why does the drug pipeline still matter if there is a buyout?

The cash part depends mainly on closing the deal. The possible extra CVR value depends on the OX2R program reaching the required clinical and regulatory milestones.